SILEXION THERAPEUTICS CORP Long-term Line of Credit
SILEXION THERAPEUTICS CORP (SLXN) had Long-term Line of Credit of ILS 87.00 thousand as of 2026-06-30, per its 10-Q filed 2026-08-14.
Financial Statements › Balance Sheet › Liabilities
us-gaap:LineOfCredit · last filed 2026-08-14
- 2026-06-30: Long-term Line of Credit 87.00K ILS.
- 2026-03-31: Long-term Line of Credit 86.00K ILS.
- 2025-12-31: Long-term Line of Credit 86.00K ILS.
- 2025-09-30: Long-term Line of Credit 85.00K ILS.
ILS
| Period end | Long-term Line of Credit |
|---|---|
| 2026-06-30 | 87.00K ILS 10-Q · filed 2026-08-14 |
| 2026-03-31 | 86.00K ILS S-1/A · filed 2026-08-10 |
| 2025-12-31 | 86.00K ILS S-1/A · filed 2026-08-10 |
| 2025-09-30 | 85.00K ILS 10-Q · filed 2025-11-12 |
| 2025-06-30 | 86.00K ILS 10-Q · filed 2025-08-12 |
| 2024-12-31 | 95.00K ILS 8-K · filed 2025-08-20 |
| 2024-09-30 | 85.00K ILS 10-Q · filed 2024-11-14 |
USD
| Period end | Long-term Line of Credit |
|---|---|
| 2025-03-31 | $95.00K 10-Q · filed 2025-05-13 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| CURIS INC (CRIS) | United States | $0.002B | -0.05 |
| Calidi Biotherapeutics, Inc. (CLDI) | United States | $0.003B | |
| VivoSim Labs, INC. (VIVS) | United States | $0.003B | |
| WINDTREE THERAPEUTICS INC /DE/ (WINT) | United States | $0.003B | -0.32 |
| PharmaCyte Biotech, Inc. (PMCB) | United States | $0.005B | |
| AIM ImmunoTech Inc. (AIM) | United States | $0.006B | |
| CREATIVE MEDICAL TECHNOLOGY HOLDINGS, INC. (CELZ) | United States | $0.006B | |
| CERO THERAPEUTICS HOLDINGS, INC. (CERO) | United States | $0.007B | |
| TScan Therapeutics, Inc. (TCRX) | United States | $0.008B | -1.23 |
| Senti Biosciences Holdings, Inc. (SNTI) | United States | $0.011B | -0.70 |